Phase 2 Tuberculosis Trial, Recruiting NCT07303699 Sponsor: Obafemi Awolowo University Teaching Hospital Condition: Tuberculosis
Back to Tuberculosis

Phase 2 Tuberculosis Trial, Recruiting

NCT07303699
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Your sputum (mucus/phlegm) test came back positive for TB bacteria, confirmed by either a Gene Xpert test or a microscope test
  • You have either never been treated for TB before, or you have taken TB medication for less than 2 weeks
  • You are aged 12 years or older
  • You have a stable home address that can be visited by the study team
  • You are willing to take part in the study and agree to have a blood sample taken for an HIV test
  • Your recent blood test results (taken within the last 14 days) show that your liver, kidneys, blood cells, and potassium levels are all within acceptable ranges (confirm with trial site for exact values)
  • You have given your informed consent to participate in the study

Who may not be able to join:

  • You are known or suspected to have a drug-resistant form of TB
  • You are living with HIV
  • Your health condition is so poor that starting treatment cannot be delayed
  • You have a serious ongoing health condition such as heart failure, coronary heart disease, or irregular heartbeat
  • You have a known or family history of bleeding or clotting problems
  • Your kidneys are not working properly, based on a specific blood test result (confirm with trial site)
  • You have a muscle condition called myositis, or a specific muscle-related blood marker is significantly elevated
  • You are in a very critical or end-of-life health state
  • You have TB that has spread to the brain (TB meningitis)
  • You have diabetes
  • You have high blood pressure
  • You are currently taking TB medication
  • You have any other long-term illness that requires you to take daily medication
  • You have a psychiatric (mental health) illness
  • You are pregnant or currently breastfeeding
  • You currently smoke tobacco or use tobacco in any form
  • You drink alcohol or have a problem with alcohol use
  • You regularly consume energy drinks, tea, coffee, cocoa, kola nuts, grapefruit or grapefruit juice, bitter oranges, garlic supplements, St. John's Wort, or similar herbal supplements, or take medications such as theophylline — and would not be able to stop these for the duration of the study
  • You are currently enrolled in another clinical treatment trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Olanisun O Adewole, MD, Obafemi Awolowo University / Teaching Hospital, Ile Ife, Nigeria

Phone: +2348034074930

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Obafemi Awolowo University Teaching Hospital
Registry
ClinicalTrials.gov
Start date
3 January 2026
Est. completion
30 March 2027

Where this trial is recruiting

Nigeria

Primary endpoints

Area under the plasma concentration versus time curve (AUC 0-24) for atorvastatin acid, rifampicin, isoniazid and their metabolites at steady state; Peak Plasma Concentration (Cmax) for atorvastatin acid, rifampicin, isoniazid and their metabolites at steady state; Plasma Clearance (Cl/F) in mL/min of atorvastatin acid, rifampicin, isoniazid and their metabolites at steady state

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov